2021
Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study
Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J, Montaner JSG, Hogg RS, Lima VD. Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ Open 2021, 11: e041734. PMID: 33419911, PMCID: PMC7799128, DOI: 10.1136/bmjopen-2020-041734.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsBritish ColumbiaCohort StudiesFemaleHIV InfectionsHumansMaleRetrospective StudiesYoung AdultConceptsHIV-negative controlsAge-associated comorbiditiesPopulation-based cohort studyCohort studyPrevalence trendsDiagnosis of comorbiditiesHIV-negative counterpartsNon-AIDS comorbiditiesHIV-negative individualsProvincial administrative databasesHIV care modelAdministrative health dataAge-associated conditionsLongitudinal cohort dataEarly ageAIDS comorbiditiesLiver diseaseEligible participantsLung diseaseAdministrative databasesHigh prevalencePLWHComorbiditiesCare modelKruskal-Wallis test
2020
Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis
McGinnis KA, Skanderson M, Edelman EJ, Gordon AJ, Korthuis PT, Oldfield B, Williams EC, Wyse J, Bryant K, Fiellin DA, Justice AC, Kraemer KL. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug And Alcohol Dependence 2020, 217: 108272. PMID: 32971391, PMCID: PMC7757793, DOI: 10.1016/j.drugalcdep.2020.108272.Peer-Reviewed Original ResearchConceptsAlcohol use disorderDetectable VLVisits/monthUse disordersVeterans Aging Cohort Study (VACS) dataCohort study dataRace/ethnicityUndetectable VLMedian ageTreatment initiationMedication treatmentImproved adherenceHIVBehavioral treatmentFirst monthIntensity groupTreatment intensityMonthsImpact of BehavioralOutcomesLinear regression modelsLongitudinal analysisVisitsVLAdherenceAlcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence?
Williams EC, McGinnis KA, Rubinsky AD, Matson TE, Bobb JF, Lapham GT, Edelman EJ, Satre DD, Catz SL, Richards JE, Bryant KJ, Marshall BDL, Kraemer KL, Crystal S, Gordon AJ, Skanderson M, Fiellin DA, Justice AC, Bradley KA. Alcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence? AIDS And Behavior 2020, 25: 203-214. PMID: 32617778, PMCID: PMC7775874, DOI: 10.1007/s10461-020-02950-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlcohol DrinkingAnti-Retroviral AgentsCohort StudiesFemaleHIV InfectionsHumansMaleMedication AdherenceMiddle AgedConceptsAlcohol useAntiretroviral therapyLow-level alcohol useInitial adherenceAntiretroviral adherenceAdherence interventionsAdherence decreasesAlcohol use increasesScreening scoresLongitudinal associationsAdherencePLWHHIVAnnual changesLinear regression modelsStable scoresRegression modelsScoresSmall annual changesDynamic longitudinal associationsAssociationUse increasesPatientsTherapyPolypharmacy in HIV: recent insights and future directions.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Current Opinion In HIV And AIDS 2020, 15: 126-133. PMID: 31833963, PMCID: PMC7543953, DOI: 10.1097/coh.0000000000000608.Commentaries, Editorials and LettersConceptsSeverity of illnessInappropriate medicationsDrug interactionsActual adverse eventsSubstance useTotal drug burdenMechanism of injuryElectronic health recordsNonantiretroviral medicationsUpdate findingsMore medicationsAdverse eventsDrug burdenClinical managementPolypharmacyDirect biomarkerMedicationsModifiable mechanismsPWHSicker individualsHealth recordsStrong associationHIVInjuryIllness
2019
Effect estimates in randomized trials and observational studies: comparing apples with apples
Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA. Effect estimates in randomized trials and observational studies: comparing apples with apples. American Journal Of Epidemiology 2019, 188: 1569-1577. PMID: 31063192, PMCID: PMC6670045, DOI: 10.1093/aje/kwz100.Peer-Reviewed Original Research
2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatientsHIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers
Farhadian S, Jalbert E, Deng Y, Goetz MB, Park LS, Justice A, Dubrow R, Emu B. HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 337-344. PMID: 29140874, PMCID: PMC5807137, DOI: 10.1097/qai.0000000000001595.Peer-Reviewed Original ResearchConceptsCD8 T cellsT-cell markersCD4 T cellsHIV infectionT cellsAntiretroviral therapyEffector memory CD4 T cellsImmune systemVeterans Aging Cohort StudyMemory CD4 T cellsNaive CD4 T cellsAging Cohort StudyT cell subsetsT-cell phenotypeCopies/mLCross-sectional studyRace/ethnicityChronic HIVUninfected subjectsUninfected menCohort studyHIV diseaseHigher proportionHIV serostatusHIV status
2017
Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?
Justice AC, Erlandson KM, Hunt P, Landay A, Miotti P, Tracy RP. Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era? The Journal Of Infectious Diseases 2017, 217: 521-528. PMID: 29165684, PMCID: PMC5853399, DOI: 10.1093/infdis/jix586.Peer-Reviewed Original ResearchConceptsHIV infectionLong-term treatment toxicityAntiretroviral therapy eraChronic HIV infectionLow-level inflammationT-cell countsForms of cancerART initiationTherapy eraTreatment toxicityImmune dysfunctionRenal diseaseLiver diseaseChronic inflammationIntervention trialsClinical managementNeurocognitive declineCardiovascular diseaseClinical trialistsUninfected individualsRNA suppressionHIV researchWeight gainTranslational scientistsBiomarkersTen-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries
Youn B, Shireman TI, Lee Y, Galárraga O, Rana AI, Justice AC, Wilson IB. Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS 2017, 31: 1697-1707. PMID: 28700393, PMCID: PMC5625296, DOI: 10.1097/qad.0000000000001541.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Retroviral AgentsFemaleHIV InfectionsHumansMaleMedicaidMedication AdherenceMiddle AgedRetrospective StudiesUnited StatesYoung AdultConceptsAngiotensin II receptor blockersII receptor blockersHIV patientsControl medicationTherapy persistenceReceptor blockersEnzyme inhibitors/angiotensin II receptor blockersCox proportional hazards modelNon-HIV medicationsUS Medicaid beneficiariesHIV-negative controlsRetrospective cohort studyKaplan-Meier curvesDuration of treatmentProportional hazards modelTen-year trendsSecular trendsART initiatorsCohort studyHazard ratioMedian timeFill dateMedicaid claimsMedicaid beneficiariesAdjusted modelComplementary and Alternative Medicine Among Persons living with HIV in the Era of Combined Antiretroviral Treatment
Halpin SN, Carruth EC, Rai RP, Jennifer Edelman E, Fiellin DA, Gibert C, Gordon KS, Huang W, Justice A, Marconi VC, Rimland D, Perkins MM. Complementary and Alternative Medicine Among Persons living with HIV in the Era of Combined Antiretroviral Treatment. AIDS And Behavior 2017, 22: 848-852. PMID: 28733920, PMCID: PMC5939585, DOI: 10.1007/s10461-017-1866-7.Peer-Reviewed Original ResearchConceptsCAM useAlternative medicineVeterans Aging Cohort StudyAntiretroviral therapy eraCombined Antiretroviral TreatmentAging Cohort StudyTherapy eraBothersome symptomsCohort studyAntiretroviral treatmentCAM usersHigh prevalenceMore benzodiazepinesLess nicotineHIVTraditional treatmentPLWHCliniciansTreatmentMedicineOpioidsSymptomsBenzodiazepinesPrevalenceNicotineSleep Disturbance Among HIV-Infected and Uninfected Veterans
Womack JA, Murphy TE, Bathulapalli H, Akgün KM, Gibert C, Kunisaki KM, Rimland D, Rodriguez-Barradas M, Yaggi H, Justice AC, Redeker NS. Sleep Disturbance Among HIV-Infected and Uninfected Veterans. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 74: e117-e120. PMID: 27906767, PMCID: PMC5326673, DOI: 10.1097/qai.0000000000001264.Peer-Reviewed Original Research
2016
The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy
Edelman E, Gordon K, Tate J, Becker W, Bryant K, Crothers K, Gaither, Gibert C, Gordon A, Marshall B, Rodriguez‐Barradas M, Samet J, Skanderson M, Justice A, Fiellin D. The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy. HIV Medicine 2016, 17: 728-739. PMID: 27186715, PMCID: PMC5053822, DOI: 10.1111/hiv.12377.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmunosuppressive AgentsLongitudinal StudiesMaleMiddle AgedConceptsCD4 cell countBaseline CD4 cell countCell countPrescribed opioidsImmunosuppressive propertiesVeterans Aging Cohort Study (VACS) dataCD4 cell count recoveryAntiretroviral therapy responseCell count recoveryShort-term opioidsViral load suppressionCohort study dataOverall disease severityYear of initiationPrimary independent variableOpioid durationAntiretroviral therapyCount recoveryComorbid conditionsPharmacy dataOpioid propertiesTherapy responseOpioidsPatientsHIVTime trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era
Park LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, Rodriguez-Barradas MC, Goetz MB, Bedimo RJ, Brown ST, Justice AC, Dubrow R. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era. AIDS 2016, 30: 1795-1806. PMID: 27064994, PMCID: PMC4925286, DOI: 10.1097/qad.0000000000001112.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Retroviral AgentsFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedNeoplasmsNorth AmericaProspective StudiesYoung AdultConceptsAntiretroviral therapy eraIncidence rateUninfected personsTherapy eraCohort studyCancer incidenceVeterans Aging Cohort StudyImproved immune functionLarge HIV cohortProspective cohort studyCrude incidence rateIncident cancer diagnosisRisk factor prevalenceAging Cohort StudyEvidence-based screeningIncidence rate ratiosIncidence time trendsFuture cancer incidenceTime trendsHIV/AIDSTrend P valueCancer groupingsSpecific cancer typesART regimensHIV careD-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events
Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O’Bryan T, Rimland D, Justice AC, Agan BK, . D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLOS ONE 2016, 11: e0152588. PMID: 27088215, PMCID: PMC4835105, DOI: 10.1371/journal.pone.0152588.Peer-Reviewed Original ResearchConceptsNon-AIDS diseasesNon-AIDS eventsD-dimer levelsHIV viral suppressionART initiationAntiretroviral therapyViral suppressionD-dimerInterleukin-6Time pointsUS Military HIV Natural History StudyMulticenter observational cohortMedian CD4 countIL-6 levelsMean percent increaseActive duty military personnelNatural history studiesDuty military personnelCD4 countHIV seroconversionHIV levelsMedian durationObservational cohortMedian timeExcess riskMortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnti-Retroviral AgentsCD4 Lymphocyte CountCohort StudiesFemaleHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedYoung AdultConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortality
2015
Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin DA. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 223-233. PMID: 26009831, PMCID: PMC4446730, DOI: 10.1097/qai.0000000000000591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAnti-Retroviral AgentsBenzodiazepinesCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedProspective StudiesSurvival AnalysisConceptsLong-term opioidsMorphine equivalent daily doseOpioid receiptRisk of deathLong-term prescriptionUninfected patientsOpioid dosesAntiretroviral therapyHazard ratioDaily dosePropensity scoreHigher opioid dosesCause mortalityHIV statusAvailable patientsMortality riskOpioidsHIVPatientsProspective analysisMortalityBenzodiazepinesDosesDeathRiskWeight Change After Antiretroviral Therapy and Mortality
Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, Logeais M, Rimland D, Rodriguez-Barradas MC, Ruser C, Justice AC. Weight Change After Antiretroviral Therapy and Mortality. Clinical Infectious Diseases 2015, 60: 1852-1859. PMID: 25761868, PMCID: PMC4542664, DOI: 10.1093/cid/civ192.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsBody Mass IndexBody WeightFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedOverweightProspective StudiesVeteransWeight GainWeight LossConceptsBaseline body mass indexVeterans Aging Cohort StudyNormal weight patientsART initiationWeight gainWeight changeHuman immunodeficiency virus-infected patientsLower mortalityDisease severityAntiretroviral therapy initiationMultivariable Cox modelVirus-infected patientsAging Cohort StudyMedian weight changeBody mass indexYears of ARTGreater disease severityVACS IndexAntiretroviral therapyTherapy initiationBaseline weightCohort studyObese patientsSurvival benefitHemoglobin levels
2014
Observational Research on NCDs in HIV-Positive Populations
Petersen M, Yiannoutsos CT, Justice A, Egger M. Observational Research on NCDs in HIV-Positive Populations. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: s8-s16. PMID: 25117964, PMCID: PMC4317266, DOI: 10.1097/qai.0000000000000253.Peer-Reviewed Original ResearchConceptsNCD risk factorsNoncommunicable diseasesRisk factorsKey NCD risk factorsBurden of NCDsCost-effective prevention strategiesPrevention of NCDsEfficient care strategyIncomplete outcome ascertainmentHIV-positive populationModifiable risk factorsBurden of morbidityRisk of deathPopulation-based sampleHealth system levelClinical decision makingWeb of causationNCD comorbidityHIV-negativeHIV infectionMiddle-income countriesRandomized trialsOutcome ascertainmentHigh-income countriesPrevention strategiesHepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNA
2013
Validation of an algorithm to identify antiretroviral‐naïve status at time of entry into a large, observational cohort of HIV‐infected patients
Gandhi NR, Tate JP, Rodriguez‐Barradas M, Rimland D, Goetz MB, Gibert C, Brown ST, Mattocks K, Justice AC. Validation of an algorithm to identify antiretroviral‐naïve status at time of entry into a large, observational cohort of HIV‐infected patients. Pharmacoepidemiology And Drug Safety 2013, 22: 1019-1025. PMID: 23836591, PMCID: PMC3831617, DOI: 10.1002/pds.3476.Peer-Reviewed Original ResearchConceptsART-naïve patientsViral load thresholdMedical record reviewAntiretroviral treatmentMedical recordsHIV cohortObservational cohortRecord reviewVeterans Aging Cohort Study Virtual CohortVirtual cohortPrevious antiretroviral treatmentLaboratory dataPatients' medical recordsPositive predictive value 87Cohort entryAdverse eventsHIV outcomesRandomized trialsRetrospective studyAdverse reactionsTime of entryCopies/ART treatmentTreatment statusTreatment history